EP2540742A4 - Anticorps monoclonaux de la protéine anti-cyr61 et utilisations de ceux-ci - Google Patents

Anticorps monoclonaux de la protéine anti-cyr61 et utilisations de ceux-ci

Info

Publication number
EP2540742A4
EP2540742A4 EP10834216.3A EP10834216A EP2540742A4 EP 2540742 A4 EP2540742 A4 EP 2540742A4 EP 10834216 A EP10834216 A EP 10834216A EP 2540742 A4 EP2540742 A4 EP 2540742A4
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibodies
protein monoclonal
cyr61 protein
cyr61
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10834216.3A
Other languages
German (de)
English (en)
Other versions
EP2540742A1 (fr
Inventor
Ningli Li
Baihua Shen
Li Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Immunology
SHANGHAI INST OF IMMUNOLOGY
Original Assignee
Shanghai Institute of Immunology
SHANGHAI INST OF IMMUNOLOGY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN200910199937A external-priority patent/CN101709088A/zh
Priority claimed from CN200910199938A external-priority patent/CN101709089A/zh
Application filed by Shanghai Institute of Immunology, SHANGHAI INST OF IMMUNOLOGY filed Critical Shanghai Institute of Immunology
Publication of EP2540742A1 publication Critical patent/EP2540742A1/fr
Publication of EP2540742A4 publication Critical patent/EP2540742A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP10834216.3A 2009-12-04 2010-11-27 Anticorps monoclonaux de la protéine anti-cyr61 et utilisations de ceux-ci Withdrawn EP2540742A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910199937A CN101709088A (zh) 2009-12-04 2009-12-04 抗Cyr61蛋白的单克隆抗体及其应用
CN200910199938A CN101709089A (zh) 2009-12-04 2009-12-04 抗Cyr61蛋白的单克隆抗体及其应用
PCT/CN2010/079208 WO2011066783A1 (fr) 2009-12-04 2010-11-27 Anticorps monoclonaux de la protéine anti-cyr61 et utilisations de ceux-ci

Publications (2)

Publication Number Publication Date
EP2540742A1 EP2540742A1 (fr) 2013-01-02
EP2540742A4 true EP2540742A4 (fr) 2014-02-12

Family

ID=44114613

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10834216.3A Withdrawn EP2540742A4 (fr) 2009-12-04 2010-11-27 Anticorps monoclonaux de la protéine anti-cyr61 et utilisations de ceux-ci

Country Status (2)

Country Link
EP (1) EP2540742A4 (fr)
WO (1) WO2011066783A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413735B1 (en) * 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
WO2001098359A2 (fr) * 2000-06-21 2001-12-27 Wyeth Cyr61 utilise comme cible dans le traitement et le diagnostic du cancer du sein
WO2002026193A2 (fr) * 2000-09-29 2002-04-04 Wyeth Utilisation de cyr61 dans le traitement et le diagnostic des leiomyomes uterins chez la femme
CN101709089A (zh) * 2009-12-04 2010-05-19 上海市免疫学研究所 抗Cyr61蛋白的单克隆抗体及其应用
CN101709088A (zh) * 2009-12-04 2010-05-19 上海市免疫学研究所 抗Cyr61蛋白的单克隆抗体及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Cyr61 (N-16): sc-8560", XP002718211, Retrieved from the Internet <URL:http://datasheets.scbt.com/sc-8560.pdf> [retrieved on 20131219] *
ANONYMOUS: "Human Cyr61/CCN1 Antibody Monoclonal Mouse IgG1 Clone # 365108 Catalog Number: MAB4055", 6 May 2010 (2010-05-06), XP055094502, Retrieved from the Internet <URL:http://www.rndsystems.com/pdf/MAB4055.pdf> [retrieved on 20131219] *
ANONYMOUS: "new products: R&D Systems New Products March 2007", 1 March 2007 (2007-03-01), XP055094501, Retrieved from the Internet <URL:http://www.woongbee.com/0NewHome/RnD/Literature/NewPro/200703_5886.pdf> [retrieved on 20131219] *
See also references of WO2011066783A1 *
ZHANG QIUYU ET AL: "A Critical Role of Cyr61 in Interleukin-17-Dependent Proliferation of Fibroblast-like Synoviocytes in Rheumatoid Arthritis", ARTHRITIS & RHEUMATISM, JOHN WILEY & SONS, INC, US, vol. 60, no. 12, 1 December 2009 (2009-12-01), pages 3602 - 3612, XP009148188, ISSN: 0004-3591, [retrieved on 20091130], DOI: 10.1002/ART.24999 *

Also Published As

Publication number Publication date
WO2011066783A1 (fr) 2011-06-09
EP2540742A1 (fr) 2013-01-02

Similar Documents

Publication Publication Date Title
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
IL232008A (en) Protein isolate heterodimer alpha-4-in-cell-7-specific antigen-binding and various aspects thereof
HK1176940A1 (zh) 單克隆抗體及其診斷用途
IL215649A (en) Monoclonal antibodies against TNF-α and their use
PL2510011T3 (pl) Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
EP2494062A4 (fr) Anticorps anti-glp-1r et leurs utilisations
EP2525813A4 (fr) Anticorps anti-ilt5 et fragments d&#39;anticorps se liant à ilt5
HK1168871A1 (zh) 單克隆抗體
EP2593475A4 (fr) Anticorps monoclonal anti-addl et ses utilisations
IL215291A0 (en) NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
EP2399934A4 (fr) Nouvel anticorps monoclonal, et son utilisation
EP2475383A4 (fr) Anticorps humanisés spécifiques de peptide-6 dérivé de hsp65, procédés et utilisations de ceux-ci
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
EP2484694A4 (fr) Anticorps monoclonal contre le polypeptide h1g1 humain
EP2540742A4 (fr) Anticorps monoclonaux de la protéine anti-cyr61 et utilisations de ceux-ci
IL218438A0 (en) Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/577 20060101ALI20131220BHEP

Ipc: A61P 19/04 20060101ALI20131220BHEP

Ipc: C07K 16/18 20060101AFI20131220BHEP

Ipc: A61P 29/00 20060101ALI20131220BHEP

Ipc: A61K 39/395 20060101ALI20131220BHEP

Ipc: A61P 35/00 20060101ALI20131220BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20140114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140812